City

Cleveland (1)

Condition

Gastroenteropancreatic Neuroendocrine Neoplasm (2)

Anal Squamous Cell Carcinoma (1)

Castrate Resistant Prostate Cancer (1)

Colorectal Neoplasms (1)

Gastroenteropancreatic Neuroendocrine Tumor (1)

Malignant Pleural Mesothelioma (1)

Neuroendocrine Carcinoma of Prostate (1)

Small Cell Lung Carcinoma (1)

Soft Tissue Sarcoma (1)

Overall Status

Not yet recruiting (2)

Sign in for free

Phase

phase 1 (1)

phase 2 (1)

Sponsor

Amr Mohamed MD (1)

Translational Research in Oncology (1)

Collaborator

Bayer (1)

Novartis (1)

Intervention

ipilimumab (1mg/kg) (1)

nivolumab 240 mg (1)

regorafenib in combination with tislelizumab (1)

tq formula (black seed oil capsules) (1)

Study Documents

Intervention Type

combination product (1)

drug (1)

Funder Type

Other (2)

Study Type

Interventional (2)

gastroenteropancreatic neuroendocrine neoplasm

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Anal Squamous Cell Carcinoma, Colorectal Tumors, Soft Tissue Sarcoma Trial (Regorafenib in combination with Tislelizumab)

Not yet recruiting

Anal Squamous Cell Carcinoma
+7 more

Regorafenib in combination with Tislelizumab

(no location specified)

Oct 12, 2022

Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Trial in Cleveland (TQ Formula (black

Not yet recruiting

Gastroenteropancreatic Neuroendocrine Tumor
Gastroenteropancreatic Neuroendocrine Neoplasm

TQ Formula (black seed oil capsules)
+2 more

Cleveland, Ohio

University hospitals Seidman Cancer Center, Case Comprehensive C

Aug 12, 2022